Document 0322
 DOCN  M9550322
 TI    Intracellular immunization of human fetal cord blood stem/progenitor
       cells with a ribozyme against human immunodeficiency virus type 1.
 DT    9505
 AU    Yu M; Leavitt MC; Maruyama M; Yamada O; Young D; Ho AD; Wong-Staal F;
       Department of Medicine, University of California, San Diego, La; Jolla
       92093-0665.
 SO    Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):699-703. Unique Identifier :
       AIDSLINE MED/95148605
 AB    Successful treatment of human immunodeficiency virus infection may
       ultimately require targeting of hematopoietic stem cells. Here we used
       retroviral vectors carrying the ribozyme gene to transduce CD34+ cells
       from human fetal cord blood. Transduction and ribozyme expression had no
       apparent adverse effect on cell differentiation and/or proliferation.
       The macrophage-like cells, differentiated from the stem/progenitor cells
       in vitro, expressed the ribozyme gene and resisted infection by a
       macrophage tropic human immunodeficiency virus type 1. These results
       suggest the feasibility of stem cell gene therapy for human
       immunodeficiency virus-infected patients.
 DE    Antigens, CD/*ANALYSIS  Base Sequence  Cell Differentiation  Cell
       Division  Cells, Cultured  Colony-Forming Units Assay  DNA Polymerase
       III/GENETICS  Fetal Blood/CYTOLOGY  Genetic Vectors  *Hematopoietic Stem
       Cells/IMMUNOLOGY  Human  HIV-1/*PHYSIOLOGY  Immunomagnetic Separation
       Macrophages/*VIROLOGY  Molecular Sequence Data  Promoter Regions
       (Genetics)/GENETICS  Retroviridae  RNA, Catalytic/BIOSYNTHESIS/*GENETICS
       Support, U.S. Gov't, P.H.S.  Transformation, Genetic  Virus Replication
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).